161 related articles for article (PubMed ID: 15885860)
21. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
22. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
23. Novel agents for the management of myelodysplastic syndromes.
Meletis J; Viniou N; Terpos E
Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
[TBL] [Abstract][Full Text] [Related]
24. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
25. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.
Solomon SR; Savani BN; Childs R; Montero A; Boss C; Read EJ; Leitman SF; Barrett AJ
Biol Blood Marrow Transplant; 2005 Aug; 11(8):619-26. PubMed ID: 16041312
[TBL] [Abstract][Full Text] [Related]
26. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
28. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia and myelodysplastic syndromes in older patients.
Estey E
J Clin Oncol; 2007 May; 25(14):1908-15. PubMed ID: 17488990
[TBL] [Abstract][Full Text] [Related]
30. Novel therapies for myelodysplastic syndromes.
Faderl S; Kantarjian HM
Cancer; 2004 Jul; 101(2):226-41. PubMed ID: 15241818
[TBL] [Abstract][Full Text] [Related]
31. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
32. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
33. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
34. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
[TBL] [Abstract][Full Text] [Related]
36. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
[TBL] [Abstract][Full Text] [Related]
37. Treating myelodysplastic syndromes.
Ryan C; McCann S
IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
39. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
[TBL] [Abstract][Full Text] [Related]
40. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
